Key facts
- Notable investors include Bengbu Investment Group, Beijing Shengshi Hongming Investment Fund Management.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Kerui Gene Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Kerui Gene Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kerui Gene Biotechnology
Manufacturer of biotechnology-based products designed for genetic analysis purposes. The company offers testing methods, laboratory automation, and bioinformatics tools with capabilities for sample processing, data interpretation, and clinical research support, enabling healthcare and life sciences markets to access reliable diagnostic insights, improved efficiency in genetic screening workflows, and enhanced opportunities for precision medicine applications through comprehensive genomic data management and analysis.
- Sector
- Healthcare
- HQ
- Bangbu, China
- Founded
- 2023
- Employees
- 7
- Ownership
- Privately Held (backing)
Kerui Gene Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kerui Gene Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kerui Gene Biotechnology in its N-PORT filings yet. We sweep new filings monthly.